论文部分内容阅读
放射性肺炎,肺纤维化是影响放疗效果和病人生存质量的重要因素。764-3是中国医科院血研所研制的第一代抗纤维化活血化瘀中药复方提取物764-1有效成分的提纯物。为了解其对放射性肺纤维化的作用,本文进行了第一阶段的预防作用研究,并对两药的抗纤维化作用进行了比较。 实验分为单纯照射组(14Gyx线单次全肺照射),照射加药组(包括764-3,764-1两组)和正常对照组,实验结果显示,单纯照射组小鼠照后各月份组脯氨酸含量值均明显高于正常组.且随照射后时间的延
Radiation pneumonitis and pulmonary fibrosis are important factors affecting the efficacy of radiotherapy and the quality of life of patients. 764-3 is a purified product of the first generation anti-fibrosis blood and blood stasis Chinese herbal compound extract 764-1 developed by the Institute of Blood Research, Chinese Academy of Medical Sciences. In order to understand its role in radiation pulmonary fibrosis, the first phase of the prevention study was conducted and the anti-fibrotic effects of the two drugs were compared. The experiments were divided into simple radiation group (14Gyx line single pneumonization), irradiation plus drug group (including 764-3,764-1 two groups) and normal control group. The experimental results showed that mice in the simple irradiation group were photographed after each month. The content of amino acid was significantly higher than that of the normal group, and the time was delayed with irradiation.